Weight Loss Drugs: Medications That Cause or Treat It

Why Weight Loss Requires a Two-Sided Drug Discussion

Weight loss sits at an unusual clinical intersection: millions of patients actively seek it through medication, while others experience it as an alarming symptom of disease or drug side effects. Distinguishing intentional pharmacotherapy from unintended drug-induced loss is a clinical priority that shapes workup, monitoring, and treatment decisions.

The American Gastroenterological Association's 2024 clinical practice guideline on pharmacological management of obesity recommends that clinicians offer GLP-1 receptor agonists as first-line pharmacotherapy for patients with a BMI ≥30, or ≥27 with at least one weight-related comorbidity [1]. That same guideline stresses ongoing monitoring for excessive or unintended loss, especially in older adults where sarcopenia risk rises. Unintended weight loss of 5% or more over 6 to 12 months carries a broad differential diagnosis. A 2017 systematic review in the BMJ found that malignancy accounted for 15% to 37% of cases, gastrointestinal disorders for 6% to 19%, and psychiatric conditions for 9% to 24% [2]. Drug side effects are another common but under-recognized contributor, particularly with polypharmacy in older patients. The sections that follow separate medications into two categories: those prescribed to produce weight loss and those that cause it unintentionally.

FDA-Approved Medications That Treat Obesity

Six FDA-approved anti-obesity medications are available in the U.S. as of 2026, and three of them, all GLP-1 or GIP/GLP-1 receptor agonists, dominate prescribing because of their superior efficacy in randomized trials. The rest remain options for patients who cannot tolerate or access the newer agents.

Semaglutide (Wegovy). The STEP-1 trial (N=1,961) randomized adults with obesity to semaglutide 2.4 mg subcutaneous weekly or placebo for 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% with placebo (P<0.001) [3]. Gastrointestinal side effects, mainly nausea and diarrhea, occurred in roughly 44% of semaglutide-treated patients but were mostly mild to moderate and transient.

Tirzepatide (Zepbound). SURMOUNT-1 (N=2,539) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly against placebo in adults with BMI ≥30 (or ≥27 with a comorbidity) over 72 weeks. The 15 mg group achieved 22.5% mean weight loss compared to 3.1% for placebo [4]. This trial established tirzepatide as the most effective injectable anti-obesity agent by percentage weight reduction in a phase 3 program.

Orlistat (Xenical/Alli). Orlistat inhibits pancreatic lipase, reducing dietary fat absorption by approximately 30%. In the XENDOS trial (N=3,305), orlistat 120 mg three times daily with meals produced 5.8 kg more weight loss than placebo at four years, with a 37.3% relative risk reduction in type 2 diabetes incidence [5]. Oily stools and fecal urgency limit adherence.

Naltrexone-bupropion (Contrave). The COR-I trial (N=1,742) showed 6.1% mean weight loss with naltrexone 32 mg/bupropion 360 mg versus 1.3% for placebo at 56 weeks [6]. Nausea is the most frequent adverse event, reported in about 33% of treated patients.

Phentermine-topiramate (Qsymia). CONQUER (N=2,487) demonstrated 9.8% mean weight loss with the highest dose (phentermine 15 mg/topiramate 92 mg) versus 1.2% for placebo at 56 weeks [7]. Paresthesias, dry mouth, and constipation are common. Topiramate is teratogenic, so the drug carries a REMS program requiring pregnancy testing.

Choosing among these agents. The Endocrine Society's 2024 guideline suggests GLP-1 or dual GIP/GLP-1 agonists as preferred first-line pharmacotherapy when the primary goal is ≥10% weight reduction [8]. Phentermine-topiramate may suit patients who prefer oral dosing. Orlistat appeals to patients wanting a non-systemic option, though its efficacy is lower. All agents should accompany lifestyle modification, not replace it.

Drugs That Cause Unintended Weight Loss

Dozens of medications across multiple therapeutic classes can produce weight loss that patients did not seek. This effect ranges from mildly inconvenient to clinically dangerous, especially in frail or elderly populations. Clinicians should review the full medication list whenever a patient presents with unexplained weight reduction.

GLP-1 receptor agonists prescribed for diabetes. Liraglutide (Victoza) and semaglutide (Ozempic) are approved for type 2 diabetes at doses lower than their obesity-indicated counterparts. Even at diabetes doses, weight loss occurs. In SUSTAIN-1, semaglutide 0.5 mg and 1.0 mg produced 3.7 kg and 4.5 kg weight loss, respectively, over 30 weeks [9]. For patients already at a healthy weight who need glucose control, this loss can become a concern.

SGLT2 inhibitors. Empagliflozin, dapagliflozin, and canagliflozin cause glycosuria, leading to caloric wasting of roughly 200 to 300 kcal per day. In EMPA-REG OUTCOME (N=7,020), empagliflozin-treated patients lost approximately 2 kg more than placebo over 48 weeks [10]. This modest loss is generally well tolerated but compounds when stacked with other weight-reducing agents.

Topiramate. Originally an anticonvulsant, topiramate causes anorexia and taste alteration through carbonic anhydrase inhibition and modulation of GABA and glutamate signaling. Weight loss of 2% to 8% of body weight has been reported across epilepsy trials at doses of 200 to 400 mg daily [11]. The effect is dose-dependent and occasionally severe enough to require discontinuation.

Stimulant medications. Amphetamine-based drugs (Adderall, Vyvanse) and methylphenidate (Ritalin, Concerta) suppress appetite centrally. A meta-analysis of 11 randomized trials in adults with ADHD found mean weight loss of 2.4 kg over 4 to 24 weeks with stimulant treatment compared to placebo [12]. In children, growth monitoring is standard practice because stimulant-related appetite suppression can impair weight gain during critical developmental periods.

Metformin. The Diabetes Prevention Program (DPP, N=3,234) showed metformin 850 mg twice daily produced 2.1 kg mean weight loss versus placebo over 2.8 years [13]. The mechanism likely involves reduced hepatic glucose output and mild appetite suppression. Weight loss with metformin is typically modest but consistent.

Selective serotonin reuptake inhibitors (SSRIs). Fluoxetine is the SSRI most associated with short-term weight loss, with some trials reporting 2 to 4 kg reduction in the first 6 months of treatment, though this effect often reverses with long-term use [14]. Sertraline and escitalopram tend to be weight-neutral or cause slight gain over time. Bupropion, technically an NDRI, produces weight loss in the range of 2 to 3 kg and is the only antidepressant included in an FDA-approved anti-obesity combination product.

Chemotherapy and targeted cancer therapies. Many oncologic agents cause profound weight loss through nausea, mucositis, altered taste, and catabolic tumor effects. This intersection makes it difficult to separate drug-induced loss from cancer-driven cachexia. The European Society for Clinical Nutrition and Metabolism (ESPEN) recommends routine nutritional screening with validated tools like the Malnutrition Universal Screening Tool for all patients starting systemic cancer therapy [15].

Diagnosing the Cause of Weight Loss

A structured approach prevents both over-investigation and missed diagnoses. The initial evaluation should start with quantifying the loss, confirming it is real (not just subjective), and distinguishing intentional from unintentional reduction.

The American Academy of Family Physicians recommends that clinicians investigate when a patient has lost ≥5% of body weight within 6 to 12 months without dieting or exercise changes [16]. First-line laboratory testing typically includes a complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone (TSH), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fasting glucose or HbA1c, and urinalysis. Age-appropriate cancer screening should be current. A thorough medication review is mandatory because drug-induced weight loss is a diagnosis of exclusion that becomes apparent only when the offending agent is identified.

"Unintentional weight loss in adults should trigger a systematic evaluation, beginning with a careful history, medication review, and targeted laboratory studies before advanced imaging," states the 2022 BMJ Best Practice guideline on the topic [2]. If initial testing is unrevealing, a watchful waiting period of 3 to 6 months with serial weight checks is reasonable for patients without red-flag symptoms such as night sweats, lymphadenopathy, or new-onset dysphagia. A 2020 cohort study in the British Journal of General Practice (N=63,973) found that unexplained weight loss in patients over age 60 was associated with a subsequent cancer diagnosis in approximately 3.3% of men and 1.6% of women within 6 months [17].

When Weight Loss Drugs Need Dose Adjustment or Discontinuation

Not every patient on an anti-obesity medication should stay at the maximum dose indefinitely. The 2024 Endocrine Society guideline recommends reassessing the risk-benefit ratio if a patient on pharmacotherapy loses more than 1 to 2 kg per week beyond the initial titration phase or if BMI drops below 25 with ongoing loss [8]. Rapid weight loss increases the risk of gallstones, with a pooled analysis of GLP-1 agonist trials finding cholelithiasis rates of 1.6% versus 0.6% with placebo [18].

Lean mass preservation matters. The STEP-1 extension data showed that approximately 25% to 40% of total weight lost with semaglutide was lean mass, a ratio consistent with caloric restriction in general [3]. Resistance training and adequate protein intake (1.0 to 1.2 g/kg/day of ideal body weight) are standard adjuncts recommended by the Obesity Medicine Association to mitigate muscle loss during pharmacotherapy [19].

For patients experiencing unintended weight loss from non-obesity medications, dose reduction is the first step. Switching within a drug class (for example, replacing topiramate with levetiracetam for seizure control) can preserve therapeutic benefit while eliminating the anorectic side effect. If the drug cannot be changed, caloric supplementation and dietitian involvement should begin early, before the patient crosses into underweight territory (BMI <18.5).

Special Populations and Weight Loss Pharmacotherapy

Older adults, adolescents, and patients with eating disorder histories each require tailored approaches to weight loss medications. The FDA approved semaglutide 2.4 mg for adolescents aged 12 and older with obesity in 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean weight loss versus 0.6% gain with placebo at 68 weeks [20]. Monitoring growth velocity and bone mineral density is recommended in this age group.

In adults over 65, the SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in patients with established cardiovascular disease and overweight or obesity without diabetes [21]. The mean age in SELECT was 61.6 years. Subgroup analyses showed consistent benefit in participants older than 65, though the trial was not powered for frailty subgroups. Sarcopenic obesity, where excess fat mass coexists with low muscle mass, demands especially cautious pharmacotherapy to avoid worsening functional decline.

Patients with a history of anorexia nervosa or bulimia nervosa should not receive anti-obesity medications. The Endocrine Society guideline explicitly lists active eating disorders as a contraindication [8]. Screening with validated instruments like the SCOFF questionnaire before prescribing is a reasonable safeguard. For patients with binge eating disorder, lisdexamfetamine (Vyvanse) holds an FDA indication specifically for moderate-to-severe BED, producing a mean reduction from 4.5 to 1.5 binge days per week compared to a reduction from 4.4 to 2.3 with placebo in a 12-week trial [22].

Building a Medication-Aware Weight Monitoring Plan

Every patient starting a drug with known weight effects, whether gain or loss, should have a baseline weight recorded and a monitoring schedule established. For anti-obesity medications, the AGA guideline recommends monthly weight checks during titration, then every 3 months once stable [1]. For drugs that cause unintended loss, quarterly weights are reasonable, with more frequent checks in patients who are already lean or frail.

A practical checklist: record baseline weight and BMI at the visit where the medication is first prescribed. Set a weight-loss alert threshold (typically ≥5% unintended loss over 6 months). Review the medication list at every visit where weight change exceeds 3%. Order baseline labs before starting GLP-1 agonists (renal function, lipase if pancreatitis history, gallbladder ultrasound if symptomatic). Patients on semaglutide or tirzepatide should report persistent vomiting, severe abdominal pain, or visual changes promptly because of rare but serious risks including pancreatitis (incidence approximately 0.2% in STEP trials) and, in rodent studies, medullary thyroid carcinoma [3].

The median time to maximum weight loss on semaglutide 2.4 mg is approximately 60 to 68 weeks, after which weight tends to plateau [3]. Discontinuation leads to regain: STEP-1 extension data showed participants regained roughly two-thirds of lost weight within one year of stopping semaglutide [23]. This rebound reinforces that obesity pharmacotherapy, like hypertension or diabetes treatment, is typically long-term.